The telehealth weight loss market shifted hard in early 2026. The March Novo Nordisk settlement pushed many compounding platforms toward branded medications, FDA warning letters went out to 30-plus telehealth and compounding companies, and Lilly began offering oral orforglipron through its direct platform at around $149 a month. What that means for someone stuck at a plateau: more options, more noise, and more reason to compare programs carefully before picking one.
I looked at nine programs specifically through the lens of someone who has already lost some weight and stalled. Price, monitoring intensity, pharmacy accountability, and flexibility matter more at that stage than they do for a first-timer.
Side-by-Side Comparison
| Provider | Starting Price (Cash) | GLP-1 Type | Physician Review | Pharmacy Transparency | Ships All 50 States | Insurance Option |
| HealthRX | Sema $99/mo, Tirz $149/mo | Compounded | ~24 hours | Named 503A pharmacy, lot-tracked | Yes, free overnight | No |
| FormBlends | Sema ~$299, Tirz ~$349 per vial | Compounded | Physician-supervised | Named 503A, published HPLC/mass spec/endotoxin results | 47 states | No |
| Mochi Health | Sema ~$99/mo, Tirz ~$199/mo | Compounded | Obesity-medicine MDs | Not publicly named | Not confirmed all 50 | No |
| Hims & Hers | Sema oral ~$249/mo, Wegovy ~$299/mo | Compounded or branded | Async | Exited compounded sema post-Mar 2026 | Yes | Yes (branded) |
| Ro Body | ~$39 first month, then $74-149/mo + meds | Branded or compounded | Async, prior-auth team | Not specified | Yes | Yes |
| Form Health | ~$299/mo + labs + meds | Branded preferred | MD + dietitian team | Not specified | Not confirmed all 50 | Partial |
| Found | ~$99/mo + meds | Compounded or branded | Coaching-heavy | Not specified | Yes | Partial |
| PlushCare | ~$19.99/mo membership + meds | Branded | Same-day visits | Standard clinical | Yes | Yes |
| Henry Meds | ~$179-249 month one | Compounded | Fast intake | Not specified | Not confirmed all 50 | No |
1. HealthRX: Best for Cash-Pay Plateaus Where Price Is the Real Obstacle
Compounded semaglutide at $99 a month is genuinely rare. Most telehealth platforms charge $150 to $250 for compounded semaglutide, and several have moved to branded-only pricing well above that. HealthRX sits at $99 for sema and $149 for tirzepatide, with no contracts and no hidden costs attached.
The pharmacy matters here. Medications dispense through Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-level tracking from production to delivery. That is not something most GLP-1 telehealth platforms publish at all. The operation also holds LegitScript certification (certificate 50087439) and meets HIPAA requirements. A physician reviews your intake within roughly 24 hours, and overnight shipping is free to all 50 states.
The trial data HealthRX references is from published trials, not its own outcomes: tirzepatide showed around 21% average body weight loss at 72 weeks in the SURMOUNT-1 study published in the New England Journal of Medicine in 2022 by Jastreboff and colleagues, semaglutide around 15% at 68 weeks in the STEP 1 study published in the same journal in 2021 by Wilding and colleagues. These are compounded medications, not FDA-approved products, so results depend on the individual and the quality of the source.
Who this fits: someone on a tight budget who needs a named, verifiable pharmacy and fast access without fighting insurance for months.
2. FormBlends: Best for Buyers Who Want Published Lab Testing
FormBlends runs a similar compounded GLP-1 model with physician oversight, but the thing that sets it apart is the documentation. The company publishes per-product purity testing: HPLC purity figures, mass spec identity confirmation, and endotoxin/sterility results. That kind of disclosure is unusual. Most telehealth GLP-1 platforms do not post this publicly.
It also carries a broader catalog than most, including peptides for recovery, longevity, and cognitive support under the same clinician supervision model.
The tradeoff is price. Per-vial pricing runs around $299 for semaglutide and $349 for tirzepatide, substantially higher than HealthRX’s monthly entry price. Shipping covers 47 states, not all 50.
*One honest note before going further: I am affiliated with both HealthRX and FormBlends. Every fact here is independently verifiable, but you should know that.*
For someone at a plateau who wants documented purity data or is already thinking about adding peptides to their routine, FormBlends earns a real look. For pure price-per-month value, HealthRX wins.
3. Mochi Health: Best for Clinical Oversight on a Budget
Mochi runs compounded semaglutide at roughly $99 a month and tirzepatide at $199, with board-certified obesity-medicine physicians doing the reviews rather than general practitioners. That specialization can matter when you are troubleshooting a plateau and need a clinician who actually understands GLP-1 dosing adjustments.
4. Hims & Hers: Best for Brand-Name Meds With Insurance
After the March 2026 settlement with Novo Nordisk, Hims & Hers moved away from compounded semaglutide and toward branded options. Injectable Wegovy runs about $299 a month, oral semaglutide around $249, and Zepbound around $399, though with insurance and a savings card the out-of-pocket cost can drop to near zero. Big name, fast onboarding, limited pharmacy detail.
5. Ro Body: Best for Prior Authorization Support
Ro charges roughly $39 for the first month and $74 to $149 a month after that, with medications billed separately. The standout is its prior-authorization team, which actively works with your insurance to get branded GLP-1s covered. That support alone saves patients real hours of phone time. Monitoring is async, so visits are not face-to-face.
6. Form Health: Best for High-Touch Coaching Alongside Medication
Form Health pairs an MD with a registered dietitian, which is the most structured combination on this list. At around $299 a month before adding labs and medications, it is also the most expensive. Worth it if behavioral coaching is the piece you have been missing. Probably overkill if you just need a prescription adjusted.
7. Found: Best for Habit-Tracking Integration
Found charges about $99 a month for platform access plus medication costs on top. The coaching layer is heavier than most, with behavioral tools and check-ins built in. Not the cheapest, but the combination of medication management and structured habit support suits people who have struggled with adherence rather than with cost.
8. PlushCare: Best for Same-Day Access to a Live Provider
PlushCare membership is $19.99 a month, and it offers same-day appointments. It focuses on branded medications and accepts insurance. If you want to talk to a real provider the same day your plateau becomes frustrating, this is the fastest path to a legitimate prescription on this list.
9. Henry Meds: Best for Fast Compounded Shipping
Henry Meds offers compounded GLP-1s at around $179 to $249 in the first month with a 24 to 72-hour shipping window. The intake is fast. Check-ins are less frequent and less structured than programs like Mochi or Form Health build into theirs. Good for someone who wants to start quickly and manage their own dosing discipline.
Final Take
For plateau-focused buyers paying cash, HealthRX’s combination of low entry pricing, named pharmacy with lot tracking, and free overnight nationwide shipping is hard to beat on value. FormBlends fills a different need, specifically published testing documentation and peptide flexibility, at a higher price. Everyone else on this list solves for something more specific: insurance navigation, clinical depth, same-day access, or coaching intensity.
Match the program to the actual gap in your current approach, not just the lowest price or the biggest ad budget.
Common Questions
Does switching from compounded semaglutide to tirzepatide actually help break a plateau?
It can. Tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide targets only GLP-1. In head-to-head trial data, tirzepatide produced roughly 6 additional percentage points of body weight loss on average. Programs like HealthRX and Mochi Health offer both, so the switch does not require changing providers or restarting intake.
Why does pharmacy transparency matter more at a plateau than at the start of a program?
Early on, any reduction in appetite tends to produce results. At a plateau, you are asking whether your dose is accurate and your medication is what it claims to be. Published lot tracking and third-party purity testing, the kind FormBlends posts and HealthRX provides through Manifest Pharmacy, give you a real answer. Generic “we use accredited pharmacies” language does not.
Which of these programs is most likely to get a branded GLP-1 covered by insurance when compounded options are no longer available?
Ro Body has the most explicit prior-authorization infrastructure of the nine, with a dedicated team that works insurance approvals actively. Hims & Hers and PlushCare also accept insurance for branded medications, but neither specifically advertises a prior-auth team the way Ro does.
If I have already been on GLP-1 therapy for a year, will these programs treat me as a new patient or pick up where I left off?
Most async platforms, including Found, Ro, and Henry Meds, use intake questionnaires that ask about prior GLP-1 use and current dose. Form Health and Mochi Health, with their physician or obesity-medicine specialist reviews, are better positioned to evaluate your history and adjust rather than defaulting to a starter dose.
How did the March 2026 Novo Nordisk settlement actually change what these platforms can prescribe?
The settlement effectively ended Hims & Hers’s compounded semaglutide offering and pushed other platforms to clarify their pharmacy relationships or pivot to branded products. Programs still offering compounded semaglutide after that date, like HealthRX and FormBlends, are doing so through 503A pharmacies operating under existing regulatory frameworks, not through the bulk-drug compounding arrangements the settlement targeted.
Sources
- Jastreboff et al., tirzepatide weight loss outcomes, NEJM 2022 (SURMOUNT-1)
- Wilding et al., semaglutide weight loss outcomes, NEJM 2021 (STEP 1)
- FDA warning letters to compounding firms, January-March 2026 (FDA.gov)
- Novo Nordisk settlement announcement, March 9, 2026 (Reuters, Novo Nordisk press release)
- Eli Lilly orforglipron consumer pricing disclosure, April 2026 (Eli Lilly investor and news releases)
- LegitScript certification database (LegitScript.com)
